CELC: FDA approval, strong trial data, and robust cash position set stage for late Q3 launch

FDA has approved REVTORPYK for HR-positive, HER2-negative advanced breast cancer supported by strong pivotal trial results and NCCN guideline inclusion. Celcuity plans a commercial launch in late Q3 2026 backed by a robust cash position following a $575M convertible note.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.